Abstract
Neoadjuvant therapy for triple negative breast cancer (TNBC) has recently generated growing interest given the more aggressive biologic characteristics of such subtype and the lack of approved targeted therapies. Systemic chemotherapy represents the mainstay of treatment for TNBC. Although neoadjuvant chemotherapy has consistently demonstrated higher response rates for TNBC compared to non-TNBC, and the pathological complete response predicts long-term outcome, most patient display residual disease with a higher risk of relapse. In order to improve the outcome of TNBC new chemotherapic combinations, including platinum agents, and different targeted agents such as antiangiogenetics, poly-ADP ribose polymerase (PARP) inhibitors and other small molecule inhibitors are being evaluated in neoadjuvant setting. Currently, the research is ongoing to further characterize TNBC from a phenotypical and molecular perspective, in order to identify potential new target agents and to individualize the treatment. In this regard, the neoadjuvant setting may represent the best potential scenario to assess the activity and the sensitivity of novel agents.
Keywords: Breast cancer, chemotherapy, neoadjuvant, targeted therapy, triple negative.
Graphical Abstract
Anti-Cancer Agents in Medicinal Chemistry
Title:Neoadjuvant Strategies for Triple Negative Breast Cancer: ‘State-of-the-art’ and Future Perspectives
Volume: 15 Issue: 1
Author(s): Luisa Carbognin, Jenny Furlanetto, Cecilia Vicentini, Rolando Nortilli, Sara Pilotto, Matteo Brunelli, Francesca Pellini, Giovanni Paolo Pollini, Emilio Bria and Giampaolo Tortora
Affiliation:
Keywords: Breast cancer, chemotherapy, neoadjuvant, targeted therapy, triple negative.
Abstract: Neoadjuvant therapy for triple negative breast cancer (TNBC) has recently generated growing interest given the more aggressive biologic characteristics of such subtype and the lack of approved targeted therapies. Systemic chemotherapy represents the mainstay of treatment for TNBC. Although neoadjuvant chemotherapy has consistently demonstrated higher response rates for TNBC compared to non-TNBC, and the pathological complete response predicts long-term outcome, most patient display residual disease with a higher risk of relapse. In order to improve the outcome of TNBC new chemotherapic combinations, including platinum agents, and different targeted agents such as antiangiogenetics, poly-ADP ribose polymerase (PARP) inhibitors and other small molecule inhibitors are being evaluated in neoadjuvant setting. Currently, the research is ongoing to further characterize TNBC from a phenotypical and molecular perspective, in order to identify potential new target agents and to individualize the treatment. In this regard, the neoadjuvant setting may represent the best potential scenario to assess the activity and the sensitivity of novel agents.
Export Options
About this article
Cite this article as:
Carbognin Luisa, Furlanetto Jenny, Vicentini Cecilia, Nortilli Rolando, Pilotto Sara, Brunelli Matteo, Pellini Francesca, Pollini Paolo Giovanni, Bria Emilio and Tortora Giampaolo, Neoadjuvant Strategies for Triple Negative Breast Cancer: ‘State-of-the-art’ and Future Perspectives, Anti-Cancer Agents in Medicinal Chemistry 2015; 15 (1) . https://dx.doi.org/10.2174/1871520614666141019191616
DOI https://dx.doi.org/10.2174/1871520614666141019191616 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Vitamin D Analogs- Drug Design Based on Proteins Involved in Vitamin D Signal Transduction
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Recent Studies of QSAR on Inhibitors of Estrogen Receptor and Human Eosinophil Phosphodiesterase
Current Computer-Aided Drug Design Innovation in Contrast Agents for Magnetic Resonance Imaging
Current Medical Imaging Evaluation of Novel Biomarkers of Acute Kidney Injury: The Possibilities and Limitations
Current Medicinal Chemistry Lone Atrial Fibrillation- A Diagnosis of Exclusion
Current Pharmaceutical Design Status of Flavonols as P-Glycoprotein Inhibitors in Cancer Chemotherapy
Current Cancer Therapy Reviews Probiotic Beverage with Soy Isoflavone Consumption for Breast Cancer Prevention: A Case-control Study
Current Nutrition & Food Science CNS Drug Development – Lost in Translation?
Mini-Reviews in Medicinal Chemistry Lipoxygenase (LOX) Pathway: A Promising Target to Combat Cancer
Current Pharmaceutical Design Anticancer Effects of Ginsenoside Rh2: A Systematic Review
Current Molecular Pharmacology Anti-Thrombotic Properties of Tomato
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Nanoparticles Based on Plasma Proteins for Drug Delivery Applications
Current Pharmaceutical Design Autologous Mesenchymal Stem Cell Therapy in Progressive Multiple Sclerosis: An Open Label Study
Current Stem Cell Research & Therapy The Role of Endocytic Pathways on Estrogen Receptor α Intracellular Trafficking and 17β-estradiol Signaling
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Bioinformatics Comparison of G Protein of Isfahan Virus with the Same Proteins of Two Other Closely Related Viruses of the Genus Vesiculovirus
Protein & Peptide Letters Morpho-Functional Features of In-Vitro Cell Death Induced by Physical Agents
Current Pharmaceutical Design Studies on Coumarins and Coumarin-Related Compounds to Determine their Therapeutic Role in the Treatment of Cancer
Current Pharmaceutical Design Comparative Binding Analysis of Monoclonal Antibodies Against Native and Mutant Type in ErbB2 Receptor: A Theoretical Modeling Approach
Current Pharmaceutical Biotechnology Chloroform Fraction of Methanolic Extract of Seeds of <i>Annona muricata</i> Induce S Phase Arrest and ROS Dependent Caspase Activated Mitochondria-Mediated Apoptosis in Triple-Negative Breast Cancer
Anti-Cancer Agents in Medicinal Chemistry In Vitro and In Vivo Models for Analysis of Resistance to Anticancer Molecular Therapies
Current Medicinal Chemistry